Relapsed or Refractory Metastatic Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Relapsed or Refractory Metastatic Colorectal Cancer Market Outlook

Thelansis’s “Relapsed or Refractory Metastatic Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Metastatic Colorectal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Relapsed or Refractory Metastatic Colorectal Cancer Overview

Colorectal cancer (CRC) is the 3rd commonest cause of cancer death. Approximately 25% of patients have metastatic disease at diagnosis, and about 50%-60% of patients diagnosed with CRC further progressed to develop metastatic disease. Visceral obesity has been reported to affect the prognosis of CRC in men adversely. About a quarter of a contributor to genetic predisposition. The development time of CRC usually lasts from several to several years; therefore, it is essential to diagnose it early in developing the disease. Previously diagnosed with cancer, a history of colon polyps, inflammatory bowel diseases, diabetes mellitus, or cholecystectomy may lead to colorectal cancer (CRC). Surgery encompasses the primary form of treatment for colon cancer, whereas chemotherapy is used most commonly in the adjuvant setting. The 5-year overall survival for patients with localized, regional, and metastatic colon cancer is 91%, 72%, and 13%. Clinical outcomes in mCRC have improved significantly, mainly due to the identification of molecular subtypes. The median overall survival (OS) now approximates 30 months in clinical trial populations and two years in the general population. Molecular profiling of tumors is now routinely performed to identify the approximately 40% that are RAS wild type (WT) that are susceptible to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAB) therapy.

• The incidence of colorectal cancer (CRC) in the USA ranges from 40 to 45 cases per million population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: